These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 6190875)

  • 21. Specificity of the protective response induced by the slime layer of Pseudomonas aeruginosa.
    Mates A; Zand P
    J Hyg (Lond); 1974 Aug; 73(1):75-84. PubMed ID: 4213979
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sixth National Burn Seminar. Control of Pseudomonas infections by the immune processes.
    Feller I
    J Trauma; 1967 Jan; 7(1):93-5. PubMed ID: 6018140
    [No Abstract]   [Full Text] [Related]  

  • 23. Immunization of burned patients against Pseudomonas aeruginosa infection at Safdarjang Hospital, New Delhi.
    Roe EA; Jones RJ
    Rev Infect Dis; 1983; 5 Suppl 5():S922-30. PubMed ID: 6419315
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Intravitreal injection of human anti-pseudomonas globulin in pseudomonas endophthalmitis in rabbits].
    Hatano H; Tanaka N; Kawano M; Matsumoto K; Isobe Y; Inoue K
    Nippon Ganka Gakkai Zasshi; 1988 Dec; 92(12):2120-8. PubMed ID: 3266443
    [No Abstract]   [Full Text] [Related]  

  • 25. Vaccines against Pseudomonas aeruginosa infection: 2. Clinico-immunological investigations.
    Krokhina MA; Grishina IA; Panova YuM ; Terekhova RP; Severtsova MK; Yedvabnaya LS; Vaide M; Varro R; Rusanov VM; Kolker II
    Vaccine; 1985 Sep; 3(3):316-24. PubMed ID: 3933202
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic generation of antigen specific human monoclonal antibodies with therapeutical activities using active immunization.
    Lang AB; Fürer E; Senyk G; Larrick JW; Cryz SJ
    Hum Antibodies Hybridomas; 1990; 1(2):96-103. PubMed ID: 2129420
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Vaccination in pneumococcal and pseudomonas infections].
    Liu BK
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1983 Oct; 6(5):315-6. PubMed ID: 6676073
    [No Abstract]   [Full Text] [Related]  

  • 28. Symposium on infectious complications of neoplastic disease (Part II). Immunoprophylaxis and serotherapy of bacterial infections.
    Young LS
    Am J Med; 1984 Apr; 76(4):664-71. PubMed ID: 6424466
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of molecular biology on Pseudomonas aeruginosa immunization.
    Pennington JE
    J Hosp Infect; 1988 Feb; 11 Suppl A():96-102. PubMed ID: 2896754
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Protection against Pseudomonas aeruginosa infection by passive transfer of anti-flagellar serum.
    Drake D; Montie TC
    Can J Microbiol; 1987 Sep; 33(9):755-63. PubMed ID: 3121159
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Oral vaccination and multivalent vaccine against Pseudomonas aeruginosa keratitis.
    Gerke JR; Nelson JS
    Invest Ophthalmol Vis Sci; 1977 Jan; 16(1):76-80. PubMed ID: 832968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prevention of lethal pseudomonas bacteremia with epimerase-deficient E. coli antiserum.
    Ziegler EJ; McCutchan JA; Douglas H; Braude AI
    Trans Assoc Am Physicians; 1975; 88():101-8. PubMed ID: 772922
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Protective effects of affinity-purified antibody and truncated vaccines against Pseudomonas aeruginosa V-antigen in neutropenic mice.
    Moriyama K; Wiener-Kronish JP; Sawa T
    Microbiol Immunol; 2009 Nov; 53(11):587-94. PubMed ID: 19903258
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Immunization with outer membrane proteins (OprF and OprI) and flagellin B protects mice from pulmonary infection with mucoid and nonmucoid Pseudomonas aeruginosa.
    Hassan R; El-Naggar W; Abd El-Aziz AM; Shaaban M; Kenawy HI; Ali YM
    J Microbiol Immunol Infect; 2018 Jun; 51(3):312-320. PubMed ID: 28291719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Passive immunisation against Gram-negative bacilli in burns.
    Jones RJ
    Br J Exp Pathol; 1970 Feb; 51(1):53-8. PubMed ID: 4985031
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic and topical protection studies using Pseudomonas aeruginosa flagella in an ocular model of infection.
    Rudner XL; Hazlett LD; Berk RS
    Curr Eye Res; 1992 Aug; 11(8):727-38. PubMed ID: 1424719
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Immunization against experimental Pseudomonas aeruginosa and Serratia marcescens keratitis. Vaccination with lipopolysaccharide endotoxins and proteases.
    Kreger AS; Lyerly DM; Hazlett LD; Berk RS
    Invest Ophthalmol Vis Sci; 1986 Jun; 27(6):932-9. PubMed ID: 3519522
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Vaccines and immunotherapy against Pseudomonas aeruginosa.
    Döring G; Pier GB
    Vaccine; 2008 Feb; 26(8):1011-24. PubMed ID: 18242792
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Pseudomonas aeruginosa preparations for active immunization].
    Nazarchuk LV
    Vrach Delo; 1991 Jul; (7):22-7. PubMed ID: 1771827
    [No Abstract]   [Full Text] [Related]  

  • 40. Immunization with Larrea divaricata Cav. proteins elicits opsonic antibodies against Pseudomonas aeruginosa and induces phagocytic activity of murine macrophages.
    Canale FP; Dávila SDV; Sasso CV; Pellarín NW; Mattar Domínguez MA
    Microb Pathog; 2018 May; 118():257-267. PubMed ID: 29559255
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.